Chemistry:AKO-002

From HandWiki

AKO-002, or AKO002, is a combination of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocybin and an undisclosed "specific plant bioactive" which is under development for the treatment of Alzheimer's disease.[1][2][3] While the "specific plant bioactive" in the combination and the action of this compound have not been disclosed, certain plant compounds, such as the β-carboline harmine in Banisteriopsis caapi, are reversible monoamine oxidase A (MAO-A) inhibitors and inhibit the metabolism of psychedelic tryptamines, in turn potentiating their effects.[4][5][6] AKO-002 is being developed by Akome Biotech.[1][2][3] As of March 2022, the drug is in the preclinical research stage of development.[1][2]

See also

References